You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽升藥業(300485.SZ):參股公司綠竹生物重組帶狀皰疹疫苗獲批臨牀
格隆匯 08-05 11:56

格隆匯8月5日丨賽升藥業(300485.SZ)公佈,公司參股公司北京綠竹生物技術股份有限公司收到國家藥監局的《藥物臨牀試驗批准通知書》,同意申報的“重組帶狀皰疹疫苗(CHO細胞)”開展預防帶狀皰疹的臨牀試驗。

重組帶狀皰疹疫苗是指通過DNA重組技術在工程細胞中轉染帶狀皰疹病毒糖蛋白E序列,利用工程細胞表達特異性帶狀皰疹病毒糖蛋白E(gE)抗原,可刺激人體產生水痘-帶狀皰疹病毒抗體,預防和控制帶狀皰疹疾病。該產品的主要用途為成人預防帶狀皰疹。

帶狀皰疹(herpes zoster)是由長期潛伏在脊髓後根神經節或顱神經節內的水痘-帶狀皰疹病毒(varicella-zoster virus)經再激活引起的感染性皮膚病,長期影響患者日常生活。

該次獲批臨牀的重組帶狀皰疹疫苗為1.2類創新型疫苗,是與已上市重組帶狀皰疹疫苗結構不同的新抗原形式,具有免疫原性強、抗原遞呈效率高和不良反應低等潛在優勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account